Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.430 -0.290 (-7.80%)
Streaming Delayed Price Updated: 1:41 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth. 
Via The Motley Fool
News headline image
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Why Recursion Pharmaceuticals Stock Is Sinking Today ↗
Via The Motley Fool
News headline image
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? ↗
Via The Motley Fool
Topics Animal Testing Artificial Intelligence Intellectual Property
News headline image
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
News headline image
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing ↗
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
News headline image
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX ↗
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 
Via Stocktwits
Topics Animal Testing
News headline image
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today ↗
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? ↗
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug... 
Via Benzinga
News headline image
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated ↗
Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery. 
Via Stocktwits
Topics Animal Testing Artificial Intelligence
News headline image
Wondering what's happening in today's after-hours session? ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
Via The Motley Fool
Topics Bankruptcy Economy World Trade
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock ↗
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs." 
Via Benzinga
News headline image
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip ↗
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX. 
Via Benzinga
News headline image
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.